FDA Grants Fast Track Designation to PT217 for Neuroendocrine Prostate Cancer
The FDA granted fast track designation to PT217 for the treatment of patients with metastatic de novo or treatment-emergent neuroendocrine prostate cancer.
Related Articles
FDA Grants Fast Track Designation to CRB-701 in Relapsed/Refractory Cervical Cancer
CRB-701 has received FDA fast track designation for the treatment of adult patients with relapsed/refractory metastatic cervical cancer.
Myeloid effector cells in cancer
Schol et al. describe in this perspective the key role of myeloid effector cells in tumor control during successful immunotherapy. They also discuss myeloid cell tumor-rejecting…
FDA to Review sBLA for Glofitamab Plus Chemotherapy in Relapsed/Refractory DLBCL
A sBLA has been accepted for review seeking the approval of glofitamab plus gemcitabine and oxaliplatin for pretreated, transplant-ineligible patients with relapsed/refractory DLBCL.
Immediate Surgery Can Improve Long-Term Outcomes in Older Breast Cancer Patients
Immediate surgery can improve outcomes among women age 70 and older who are not receiving radiotherapy, data suggest.
Vice Chair of the B-Cell Lymphomas NCCN Guidelines Maps Critical Changes From 2024
Leo I. Gordon, MD, parses major changes to the 2024 NCCN guidelines for the treatment of patients with MCL, MZL, and follicular lymphoma.
Dr Rugo on Elacestrant-Based Combinations in ER+/HER2– Metastatic Breast Cancer
Hope S. Rugo, MD, FASCO, discusses updated safety findings from the ELEVATE trial of elacestrant-based combinations in ER+/HER2– metastatic breast cancer.
The Addition of Asciminib and Removal of Omacetaxine Mark Notable CML NCCN Guideline Updates
Neil P. Shah, MD, PhD, highlights key recent changes to the CML NCCN guidelines and details anticipated data for 2025.
Strategies That Help Patients With Cancer Cope With Anxiety – Oncology Nurse Advisor
Strategies nurses and other healthcare professionals can use to help patients with cancer cope with anxiety in inpatient and outpatient settings.
Dr Ali on the S0221 Trial of Alternative Chemo Dosing Schedules in Breast Cancer
Azka Ali, MD, discusses findings from the S0221 trial of alternative adjuvant anthracycline and taxane dosing schedules in high-risk, early breast cancer.